(Adds Zimmer Holdings, Kite Pharma, automobile stocks; UpdatesNovartis, Cempra) (For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)
Energy sector stocks led a broad selloff on Wall Street onMonday as crude prices fell to fresh five-and-a-half-year lowsand a strong dollar also weighed on other commodities. The DowJones industrial average was down 1.40 percent at17,583.4, the S&P 500 was down 1.48 percent at 2,027.79and the Nasdaq Composite was down 38.95 points, or 0.82percent, to 4,687.86
** FORD MOTOR CO, $14.8, -3.65 pct
** FIAT CHRYSLER AUTOMOBILES NV, $11.26, -3.68 pct
** HONDA MOTOR CO, $29.04, -1.86 pct
The December U.S. sales of all three automakers fell shortof market estimates. Industry executives and analysts cautionedthat sales growth will slow this year after five years of rapidrecovery from the recession.
** ZIMMER HOLDINGS INC, $115.74, +2.80 pct
Analysts at J.P. Morgan upgraded the orthopaedic devicemaker's shares to "overweight" from "neutral" and raised theirprice target on it to $136 from $120 - the highest among 25brokerages covering the stock.
Zimmer could benefit from reduced dis-synergy risk andimproved industry pricing over time if Stryker Corp pursues and ultimately reaches an agreement with Smith & NephewPlc, the analysts wrote.
The stock touched its year-high of $117.19.
** KITE PHARMA INC, $64.686, +6.73 pct
Amgen Inc and Kite Pharma said they entered into adeal to develop and market cancer immunotherapies using Amgen'scancer targets and Kite's technology platform.
** STEREOTAXIS INC, $1.87, +21.43 pct
The U.S. Food and Drug Administration approved the medicaldevice maker's catheter device, Vdrive with catheter advancementsystem, for sale in the country.
The company also received an approval from JapanPharmaceuticals and Medical Devices Agency for Odyssey datamanagement products.
** CONATUS PHARMACEUTICALS INC, $10.05, +24.23 pct
The biotechnology company said it would present results fromthree clinical trials of its lead drug Emricasan on Thursday.Conatus said it would present results from a mid-stage study ofthe drug in patients with acute-on-chronic liver failure.
** ISIS PHARMACEUTICALS INC, $67.3, +9.31 pct
Johnson & Johnson will pay the biotech company up to$835 million for an option to license three drugs targetingautoimmune diseases in the bowel.
** BRAINSTORM CELL THERAPEUTICS INC, $6.01, -19.87pct
The Israeli stem cell therapy developer's stock rose 93percent in past two trading days as data on mid-stage study ofthe company's stem cell therapy in patients with amytrophiclateral sclerosis is expected on Monday.
** ROYAL DUTCH SHELL PLC, $63.76, -4.81 pct
** TOTAL SA, $47.84, -6.49 pct
** BP PLC, $35.85, -5.95 pct
** STATOIL ASA, $16.49, -5.34 pct
** VALE SA, $7.71, -2.90 pct
** BHP BILLITON LTD, $45.6, -4.08 pct
** EXXON MOBIL CORP, $89.95, -3.10 pct
** CHEVRON CORP, $107.93, -4.13 pct
** PETROBRAS SA, $6.2, -8.28 pct
U.S.-listed stocks of the world's biggest oil and gasproducers were down premarket after oil prices dropped to freshfive-and-a-half-year lows. Oil prices have been dipping onconcerns over a surplus of global supplies and lacklusterdemand, losing more than half their value since a peak in Junelast year.
** CEMPRA INC, $26.0782, +13.93 pct
The antibiotic drug developer moved a step closer toapproval for its lead antibiotic, solithromycin, after an oralversion of the potential blockbuster met the main goal in alate-stage trial.
** NATIONAL BANK OF GREECE SA, $1.68, -8.70 pct
Political uncertainty in Greece may force the EuropeanCentral Bank to start quantitative easing as debate around thepossibility of elections later this month resulting in thecountry leaving the euro zone picked up again.
Euro fell to $1.18605 in early Asian trading onMonday, its weakest level since March 2006.
** BREITBURN ENERGY PARTNERS LP, $7.0799, -7.21 pct
The oil and gas company said on Friday it expected 2015production of 19.5-20.7 million barrels of oil equivalent (boe),up from an estimated 14.1 million boe for 2014. Breitburnforecast oil and gas capital expenses to fall to $200 million in2015 from an estimated $375 million in 2014.
** CERUS CORP, $6.7165, +3.09 pct
The biomedical product maker said red blood cells treatedwith its Intercept Blood System for acute anemia incardiovascular surgery patients met the main goal in an Europeanlate-stage trial.
** CINEMARK HOLDINGS INC, $33.94, -2.78 pct
The movie theater chain's shares could rise more than 25percent over the next year, Barron's reported in its Jan. 5edition. (Compiled by Lehar Maan; Editing by Joyjeet Das)
BP (BP.)
Smith & Nephew (SN.)
